Navigation Links
New knowledge on the pharmacology of dopamine stabilizers
Date:2/24/2012

A study from Karolinska Institutet in Sweden shows that a new drug for Huntington's disease pridopidine or dopamine stabiliser ACR16 might operate via previously unknown mechanisms of action. Researchers have found that at very low concentrations, ACR16 binds to the sigma-1 receptor, a protein in the brain important to neuronal function and survival. This new knowledge can be used to develop future treatments for schizophrenia, involuntary Parkinsonian tremors and neurodegenerative diseases.

"It's conceivable that some of the beneficial effects of dopamine stabilisers are mediated via the sigma-1 receptor," says principal investigator Daniel Marcellino of the Department of Neuroscience. "Our results suggest a formerly overlooked aspect of dopamine stabiliser pharmacology."

Dopamine stabilisers are a new class of drug substance originally developed by Swedish Nobel laureate Professor Arvid Carlsson. In clinical trials, these substances have revealed promising results against neurological and neuropsychiatric conditions that currently lack suitable treatment, such as schizophrenia and the dyskinesia (involuntary tremors) caused as an adverse effect of Parkinson's drugs.

Pridopidine or dopamine stabiliser ACR16 (also known as Huntexil), is in an advanced phase of clinical trials (phase III) for the relief of the motor symptoms of Huntington's disease, an incurable disease caused by neuronal degeneration in certain parts of the brain. The disease, which is hereditary, is characterised by motor and subsequent psychiatric disorders, leading to a protracted death. There is currently only one drug registered for the relief of Huntington's symptoms, but as it has several adverse effects there is a strong demand for alternative treatment options.

Dopamine stabilisers are thought to exert their beneficial effects primarily via the dopamine D2 receptor, which is a well-known site of action for drugs for Parkinson's disease and schizophrenia. However, in a study published recently in the scientific journal Molecular Psychiatry, researchers at Karolinska Institutet have shown that ACR16 and another dopamine stabiliser (-)-OSU6162 also bind to the sigma-1 receptor in low concentrations.

"We found that ACR16 binds to the sigma-1 receptor at concentrations 100 times lower than those reported for interaction with the D2 receptor," says Dr Marcellino. "This is extremely interesting since experimental studies have shown that sigma-1 receptor ligands have positive effects in schizophrenia and protect against cell death in neurodegenerative conditions."


'/>"/>

Contact: Katarina Sternudd
katarina.sternudd@ki.se
46-852-483-895
Karolinska Institutet
Source:Eurekalert

Related biology news :

1. Closing the gap: Journal launch brings together wound-healing knowledge
2. New scientific knowledge on juvenile diabetes
3. Researchers advance knowledge of little nano-machines in our body
4. Wallace S. Broecker wins the BBVA Foundation Frontiers of Knowledge Award in Climate Change
5. Federal scientists recognized for contributions to knowledge of bird ecology and habitat
6. Village bird study highlights loss of wildlife knowledge from one
7. German Research Minister Schavan: Rapid knowledge transfer can safe lives
8. The BBVA Foundation presents its Frontiers of Knowledge Awards
9. Peter Reich, BBVA Foundation Frontiers of Knowledge Award in Ecology
10. Studies improve knowledge of underlying brain changes caused by addiction
11. Technique finds gene regulatory sites without knowledge of regulators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 21, 2017 Vigilant Solutions , a ... enforcement agencies, announced today the appointment of retired FBI ... public safety business development. Mr. Sheridan brings ... including a focus on the aviation transportation sector, to ... position, Mr. Sheridan served as the Aviation Liaison Agent ...
(Date:3/16/2017)... Germany , March 16, 2017 CeBIT 2017 - Against identity ... Continue Reading ... Used combined in one project, multi-biometric solutions provide ... Used ... Systems) ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 /PRNewswire/ ... 23andMe , the leading personal genetics company, are ... can now provide customers with personalized nutrition plans that ... biometrics, but also genetic markers impacting how their body ... personalized food decision support platform uses biometrics such as ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... March 27, 2017 Roka Bioscience, Inc. (NASDAQ: ROKA), ... for the detection of foodborne pathogens,  today announced that ... Company Spring 2017 Convention on March 29 at 9:50am ET. ... Marquis. About Roka Bioscience ... Roka Bioscience is ...
(Date:3/27/2017)...  The global market for clinical laboratory services ... new report from Kalorama Information.  In addition to ... evaluate disease progression, monitor drug treatment and conditions, ... healthcare market research firm,s report, Clinical ... of the medical laboratory industry and the trends ...
(Date:3/27/2017)... 2017  Trovagene, Inc. (NASDAQ: TROV), a precision medicine ... Bill Welch , will be presenting at this ... AM EDT at the Essex House in ... Scientific Officer, Mark Erlander , Ph.D., will also ... The presentation will be webcast live at ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... Business Report" report to their offering. ... This report analyzes the Global market ... estimates and forecasts are provided for the period 2014 through 2022. ... The report profiles 25 companies including many key ...
Breaking Biology Technology: